Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

In recent years, I have watched people I know try to navigate our health care system while seeking treatment for pain or ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

That makes it less addictive than opioids, which were involved in about 70,000 overdose deaths for the year ending June 2024.

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but did not ...

The company’s suzetrigine is one of the most-watched medicines across all the drug pipelines in the biotech sector.

However, the company's forward-looking statements regarding the potential success of their drugs and market opportunities ... pre-clinical trials of its non-opioid pain treatments.

Naloxone, known by brand names Nyxoid or Narcan, rapidly reverses the depression of the central nervous and respiratory ...

In 2023, 24.3% of US adults had chronic pain, and 8.5% had high-impact chronic pain (HICP) that frequently limited daily ...

“Chronic abdominal pain is complex because it involves multiple mechanisms, including inflammation, altered gut motility, and heightened sensitivity of the nervous system,” Muttenhalter told IE. “The ...